NSE - Delayed Quote INR

Supriya Lifescience Limited (SUPRIYA.NS)

847.30 -22.00 (-2.53%)

At close: October 30 at 3:30:01 PM GMT+5:30

Chart Range Bar

Loading chart for SUPRIYA.NS

Previous Close 869.30
Open 869.30
Bid --
Ask --
Day's Range 841.80 - 880.45
52 Week Range 545.50 - 1,085.00
Volume 92,052
Avg. Volume 301,929
Market Cap (intraday) 68.193B
Beta (5Y Monthly) 0.63
PE Ratio (TTM) 34.37
EPS (TTM) 24.65
Earnings Date --
Forward Dividend & Yield 1.00 (0.12%)
Ex-Dividend Date Sep 4, 2026
1y Target Est 940.00

Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals in India and internationally. The company offers active pharmaceuticals ingredients in antihistamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, antihypertensive, vitamins, anti-malarial, and anti-gout areas. It also provides finished formulation products. In addition, the company offers GelHeal, a wound care solution; and Quickblue, an oral cancer detection kit. Further, it develops drugs in the areas of anti-depressant, anti-inflammatory, contrast media, hormones, antibiotic, smoking cessation, anti-diabetic/obesity, anti-ataxia, decongestant, veterinary API, anti-cancer, allogeneic hematopoietic stem cell transplantation, and anti-migraine. Supriya Lifescience Limited was founded in 1987 and is headquartered in Mumbai, India.

www.supriyalifescience.com

607

Full Time Employees

March 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .

YTD Return

SUPRIYA.NS

12.88%

S&P BSE SENSEX (^BSESN)

12.63%

1-Year Return

SUPRIYA.NS

12.88%

S&P BSE SENSEX (^BSESN)

11.78%

3-Year Return

SUPRIYA.NS

242.41%

S&P BSE SENSEX (^BSESN)

16.14%

5-Year Return

SUPRIYA.NS

101.26%

S&P BSE SENSEX (^BSESN)

25.55%

Earnings Per Share

gaap GAAP

nongaap Normalized

gaap GAAP

nongaap Normalized

Revenue vs. Earnings

yearly Annual

quarterly Quarterly

yearly Annual

quarterly Quarterly

Q1 FY27

Revenue 1.9B

Earnings --

Profit Margin 0.00%

FY26

FY27

500M

0.0%

5.0%

10.0%

15.0%

20.0%

Analyst Price Targets

850.00

940.00 Average

847.30 Current

1,030.00 High

Analyst Recommendations

Strong Buy
Buy
Hold
Underperform
Sell

Valuation Measures

  
  
 Annual 

Market Cap
Enterprise Value
Trailing P/E
Forward P/E
PEG Ratio (current)
Price/Sales (ttm)
Price/Book (mrq)
Enterprise Value/Revenue
Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

Profit Margin

22.74%
Return on Assets (ttm)

--
Return on Equity (ttm)

--
Revenue (ttm)

8.73B
Net Income Avi to Common (ttm)

1.98B
Diluted EPS (ttm)

24.65

Balance Sheet and Cash Flow

Total Cash (mrq)

788.67M
Total Debt/Equity (mrq)

0.45%
Levered Free Cash Flow (ttm)

--

ACUTAAS.NS

LATENTVIEW.NS

RATEGAIN.NS

MEDPLUS.NS

TEGA.NS

U.S. markets closed

Supriya Lifescience Limited (SUPRIYA.NS)

3.51%

-10.83%

21.93%

12.75%

12.75%

101.26%

101.26%

Supriya Lifescience Limited Overview Biotechnology / Healthcare

Full Time Employees

Fiscal Year Ends

Sector

Industry

Recent News

Performance Overview

YTD Return

1-Year Return

3-Year Return

5-Year Return

Earnings Trends

Earnings Per Share

Revenue vs. Earnings

Analyst Insights

Analyst Price Targets

Analyst Recommendations

Statistics

Valuation Measures

Financial Highlights

Profitability and Income Statement

Balance Sheet and Cash Flow

Company Insights

Research Reports

People Also Watch